PATENT CLAIM ANALYSIS

Application Number: 16193812
Application Type: Utility
Filing Date: 2018-11
Publication Date: 2019-03
Patent Classification: ["424", "722000"]

Abstract:
Drug combinations and their use are disclosed. A first drug is administered in combination with a second drug. The first drug such as fenfluramine is characterized by the formation of a metabolite including 5-HT 2B  agonists such as norfenfluramine with known adverse side effects. The second drug is in the form of a CYP inhibitor such as cannabidiol which modulates the formation of metabolite down thereby making the first drug safer.

Claim (Index 25):
A method of reducing or ameliorating seizures in a patient diagnosed with a form of refractory epilepsy, comprising:\n administering a liquid formulation of fenfluramine to the patient in an amount in the range of 0.2 mg/kg/day to 0.8 mg/kg/day; and administering cannabidiol in a liquid formulation in an amount of 0.5 mg/kg/day to 25 mg/kg/day.

Metadata:
- Claim Count in Document: 29.0
- Percentile: 98.0
- Lexical Diversity: 1.59574
- Patent Class: 424.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['13887014', '14447253', '15429646', '16140120', '15003161']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7425142252360024
- 35 USC 102 Novelty (BERT): 0.5290850750695167
- Combined Prediction Score: 0.7211713102193539
- Mean Citation Score: 339.638796
- Max Citation Score: 359.1233200000001
- Similarity Product: 290.0055038094688

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test